文章：

新辅助化疗对经病理证实淋巴结阳性与阴性患者根治性膀胱切除术生存结局的影响

Influence of Neoadjuvant Chemotherapy on Survival Outcomes of Radical Cystectomy in Pathologically Proven Positive and Negative Lymph Nodes

原文发布日期：9 October 2023

DOI: 10.3390/cancers15194901

类型: Article

开放获取: 是

英文摘要：

Patients receiving neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) typically show better survival outcomes than those undergoing immediate surgery for muscle-invasive bladder cancer. However, most studies have not considered the lymph node (LN) status when evaluating NAC’s survival benefits. This study sought to delineate the impact of NAC on patients based on their pathologically determined LN status at the time of RC. We examined data from 1395 patients treated at two departments between 1991 and 2022. Of them, 481 had positive LNs. A comparison of overall survival (OS) outcomes revealed that patients without LN involvement ((y)pN0) benefited from NAC with a hazard ratio (HR) of 0.692 (95% confidence interval [CI] 0.524–0.915). In contrast, patients with (y)pN+ showed no improvement with NAC (HR 0.927, 95%CI 0.713–1.205). Notably, patients treated with NAC for stage

摘要翻译： 

对于肌层浸润性膀胱癌患者，在根治性膀胱切除术（RC）前接受新辅助化疗（NAC）通常比直接手术的患者具有更好的生存结局。然而，大多数研究在评估NAC的生存获益时并未考虑淋巴结（LN）状态。本研究旨在根据患者在RC时病理确定的LN状态，阐明NAC对不同患者的影响。我们分析了1991年至2022年间在两个科室接受治疗的1395例患者的数据，其中481例存在淋巴结阳性。总生存期（OS）结果的比较显示，无淋巴结受累（(y)pN0）的患者可从NAC中获益，风险比（HR）为0.692（95%置信区间[CI] 0.524–0.915）。相比之下，(y)pN+患者并未因NAC而改善生存（HR 0.927，95%CI 0.713–1.205）。值得注意的是，对于分期

原文链接：

Influence of Neoadjuvant Chemotherapy on Survival Outcomes of Radical Cystectomy in Pathologically Proven Positive and Negative Lymph Nodes